资源描述
单击此处编辑母版标题样式,单击此处编辑母版文本样式,第二级,第三级,第四级,第五级,*,细胞信号转导障碍和疾病,Cellular signal transduction,膜受体介导的跨膜信号转导,核受体介导的信号转导,细胞信号转导,信息分子通过作用于受体及其信号转导分子而影响细胞生物学功能的过程。,Transmembrane signal transduction,跨膜信号转导,胞外信息分子与膜受体结合,将信息传递至胞浆或核内,调节靶细胞功能的过程。,核受体介导的信号转导,信息分子与核受体结合启动靶基因转录的过程。,Nuclear receptor-mediated signal transduction,核受体,(,Nuclear receptor,),位于胞浆或核内的受体,,激活后作为,转录因子,,在核内调节靶基因的转录。,(The primary pathways of cellular signal transduction),第一节,细胞信号转导的主要通路,(G pretein-mediated signal transduction),一、,G,蛋白介导的信号转导,(Adenylyl cyclase signal transduction pathway),(,一,),腺苷酸环化酶信号转导通路,cAMP,PKA,靶蛋白 磷酸化,腺苷酸环化酶,受体,2,受体,M,2,受体,Gs,Gi,Adenylyl cyclase signal transduction pathway,靶基因 转录,CREB,CRE,(,二,),磷脂酶,C,信号转导途径,(Phospholipase C signal transduction pathway,),靶蛋白 磷酸化,靶基因 转录,1,受体,AngII,受体,PIP,2,PKC,Ca,2,Gq,IP,3,DAG,PLC,Phospholipase C signal transduction pathway,(,T,yrosine protein kinase,-mediated signal transduction pathway),二、酪氨酸蛋白激酶 介导的信号转导途径,(Receptor tyrosine protein kinase,pathway),(,一,),受体酪氨酸蛋白激酶通路,单次跨膜受体,(胞外区、疏水跨膜区和胞内区),胞内区含多个可被磷酸化的酪氨酸残基,配体以生长因子为代表,Receptor tyrosine kinases,靶蛋白 磷酸化,GDP,GTP,MEK,Raf,靶基因 转录,ERK,(extracellular signal regulated kinase,,,ERK),Tyrosine protein kinase-mediated signal transduction pathway,受体,TPK,生长因子,P,P,Grb2,Sos,Ras,(Non-receptor tyrosine protein kinase pathway),(,二,),非受体酪氨酸蛋白 激酶信号转导通路,单次跨膜受体家族,受体不含内源性,TPK,结构域,配体以,cytokine,为代表,白介素,(,interleukin,,,IL,),干扰素,(,interferon,,,INF,),生长激素,(growth hormone,GH),细胞内信号转导通路是,JAK/STAT,参与免疫、造血和生长的调节,GH,Growth hormone receptor signaling through the JAK/STAT pathway,GH receptor,P,STAT,P,STAT,Target gene,STAT,STAT,信号转导和转录激活因子,(signal transducers and,activators of transcription),JAK,JAK,(Janus kinase),(Nuclear receptor-mediated signal transduction pathway),三、核受体介导的信号转导通路,类固醇激素受体家族,甲状腺素受体家族,分类,Nuclear receptor-mediated signal transduction pathway,Gene,Cortisol,HSP,R,R,HSP,R,R,R,HSP,HSP,R,(Dysfunction of cellular signal transduction in diseases),第二节 细胞信号转导障碍与疾病,一、受体异常与疾病,(,Receptor-based diseases,),受体病,(receptor disease),:因受体的数量、结构或调节功能变化,使受体不能正常介导配体在靶细胞中应有的效应所引起的疾病。,(Genetic disorders of receptor),遗传性受体病,因编码受体的基因突变,使受体数量或功能异常而引起的遗传性疾病。,家族性高胆固醇血症,(,familial hypercholesterolaemia,FH),1939,年,,Muller,首次报告了一个有遗传性缺陷的家系,血清胆固醇水平升高,跟腱黄色瘤,年轻时发生缺血性心脏病,因编码,LDL,(low-density lipoprotein,LDL),受体的基因突变,使细胞表面,LDL,受体减少或缺失,引起脂质代谢紊乱和动脉粥样硬化。,Concept,编码基因,19,号染色体短臂,(p13.1-13.3),含,18,个外显子和,17,个内含子,蛋白质,含,839,个氨基酸残基,21,个氨基酸残基组成的信号肽,核,粗面内质网,高尔基体,囊泡,溶酶体,核内体,(1),LDL,受体的代谢,(metabolism of LDL receptor),(2)LDL,受体突变的类型及分子机制,(classes of functional LDL-receptor defects),基因突变有,200-300,多种,基因缺失与插入,错义与无义突变,内质网受体合成减少,(impairment of receptor synthesis),受体装配及转运障碍,(impairment of the receptor movement),受体与配体结合力降低,(reduced capacity of receptor to bind lipoprotein),受体内吞缺陷,(impairment of receptor clustering and internalization),受体再循环障碍,(impairment of receptor recycling),(3),表现,(,manifestations),常染色体显性遗传,(autosomal dominant inheritance),纯合子,(homozygotes),发病率为,1/100,万,杂合子,(heterozygotes),发病率为,1/500,LDL,受体减少,血浆,LDL,水平升高,血清胆固醇,19.6,26.0 mmol/L,6.2,14.3,mmol/L,早发动脉粥样硬化,男性,,6,岁时因自幼皮肤黄色瘤就诊。患儿出生时臀部即有一绿豆粒大小之疹状黄色瘤,此后,黄色瘤渐扩展为条纹状及片状,且颈后、肘部和膑骨等肌腱附着处及眼内眦部先后出现斑块状、条纹状黄色瘤。,5,岁后双手指、足趾伸肌腱及跟腱先后出现大小不等的结节状黄色瘤。,Clinical example,患儿双手关节处腱性黄色瘤,患儿臀部和股部疹性黄色瘤,体检:,心脏听诊主动脉瓣区可闻,级收缩期杂音,实验室检查:,血清总胆固醇,(TC),21.3 mmol/L,(,2.825.95 mmol/L),甘油三酯,(TG),1.2 mmol/L,(0.561.7 mmol/L),高密度脂蛋白胆固醇,(HDL-C),0.8 mmol/L,(1.032.07 mmol/L),低密度脂蛋白胆固醇,(LDL-C),19.6 mmol/L,(2.73.2 mmol/L),Clinical example,FH,患者的血清呈乳白色,心电图示左室肥厚及心肌缺血,心脏多普勒检查显示主动脉壁增 厚、异常光斑、主动脉狭窄,7,岁时每于剧烈运动即心绞痛发作,8,岁时奔跑后突发前室间隔心肌梗死,10,岁于冠脉搭桥术后猝死。,Clinical example,二、,G,蛋白异常与疾病,(G protein-based disease),受体,G,GDP,G,GTP,效应蛋白,G,GTP,效应蛋白,G,GDP,G,蛋白活性的调节,G,GDP,G,GTP,G,蛋白激活:,GTP,与,G,相结合,G,蛋白失活:,GTP,酶水解,GTP,肠 腔,Gs,CT,霍乱,(Cholera),AC,cAMP ,Cl,-,H,2,O,Na,+,1.,机制,(mechanism),精氨酸,201,和谷氨酰胺,227,是维持,GsGTP,酶活性的关键氨基酸残基,霍乱毒素选择性催化,Gs,亚基的精氨酸,201,核糖化,(ADP-ribose),GTP,酶活性丧失,剧烈腹泻,脱水,休克,2.,表现,(,manifestations),(,Disorders of multiple signal molecules during diseases,),三、多个环节细胞信 号转导障碍与疾病,(Non-Insulin dependent diabetes mellitus,NIDDM),(,一,),非胰岛素依赖型糖尿病,糖尿病是由于胰岛素缺乏以及胰岛素抵抗,引起的糖、脂肪及蛋白质代谢紊乱的综合征。,1.,信号转导,(signal transduction),(1),胰岛素受体异常,遗传性胰岛素受体异常,自身免疫性胰岛素受体异常,2.,机制,(,mechanism,),(insulin receptor disorder),(disorders of postreceptor signal transduction),IRS-1/2,下调,编码,PI,3,K,的基因突变,(2),受体后信号转导异常,表达生长因子样物质,表达生长因子受体类,表达蛋白激酶类,表达信息传递分子类,表达核内蛋白类,(,二,),肿瘤,(Tumour),第三节 细胞信号转导调控与疾病防治,(Regulation of cellular signal transduction in prevention and treatment of disease),信号转导治疗,(Signal transduction therapy),以信号转导蛋白为靶分子对疾病进行防治。,To regulate extracellular molecules,To regulate the receptors,Agonist,antagonist,To regulate intracellular molecules,Inhibit TPKase,Ras,To regulate nuclear transcription factors,Thank you!,
展开阅读全文